ArticleJournal of pharmaceutical policy and practice2025
Could more adults than just those aged 75-79 years potentially benefit from vaccination against RSV: insights from UK data.
Andrew Vyse et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.